City
Epaper

Drug regulatory body initiates probe after US FDA flags contamination risk from India-made eyedrops

By ANI | Published: February 04, 2023 1:51 AM

After the US regulator Food and Drug Administration warned consumers "not to purchase or use EzriCare Artificial Tears due ...

Open in App

After the US regulator Food and Drug Administration warned consumers "not to purchase or use EzriCare Artificial Tears due to potential contamination", the Central Drugs Standard Control Organization (CDSCO) under the Union Health ministry and the Tamil Nadu State Drug Controller have initiated a probe into the pharma firm producing this eyedrop, a source aware of the issue said on Friday.

"Teams from CDSCO and TN State Drug Controller, comprising three officials, are on their way to the manufacturing plant located near Chennai. It's a contract manufacturing plant supplying through others to the US market. This specific drug is not sold in India," said the source.

FDA has also restricted the imports of products manufactured by Global Pharma Private Healthcare Limited.

"The import alert prevents these products from entering the United States," FDA said in a statement, adding "FDA is warning consumers and health care practitioners not to purchase and immediately stop using EzriCare Artificial Tears or Delsam Pharma's Artificial Tears due to potential bacterial contamination. Using contaminated artificial tears increases the risk of eye infections that could result in blindness or death."

The over-the-counter products, manufactured by Global Pharma Healthcare Private Limited, are intended to be 'sterile', the FDA noted.

Global Pharma has initiated a voluntary recall at the consumer level of all unexpired lots of EzriCare Artificial Tears and Delsam Pharma's Artificial Tears, the source informed further.

FDA added that it recommended this recall due to the company's current good manufacturing practice (CGMP) violations, including lack of appropriate microbial testing, formulation issues (the company manufactures and distributes ophthalmic drugs in multi-use bottles, without an adequate preservative), and lack of proper controls concerning tamper-evident packaging.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Central Drugs Standard Control OrganisationindiachennaiFood And Drug AdministrationFood products, medicinesUnited states food and drug administrationCommissioner of food and drugs administrationUsfdaIndiUk-india
Open in App

Related Stories

EntertainmentIndia to Host 'Bharat Parv' at 77th Cannes Film Festival: Showcasing Creative Opportunities

NationalLok Sabha Election 2024: I.N.D.I.A Bloc Will Win at Least 50 Seats in Uttar Pradesh, Says Rahul Gandhi

BusinessIndia Poised to Become World’s Third Largest Consumer Market by 2026 Outpacing Germany, Japan

InternationalRussia Backs Us, Questions Us Lack of Evidence Implicating India in Pannun Case

NationalINDIA Bloc Leaders to Confront EC on Voter Turnout and BJP's Use of Religious Symbols in Election Matters

National Realted Stories

NationalMamata, MK Stalin and Uddhav Thackeray Will Be in Jail if BJP Wins Lok Sabha Election 2024, Says Arvind Kejriwal

NationalBengal PDS case: ED seeks number of active card holders from food department

NationalK’taka horror: Teenage girl’s severed head found on tree branch

NationalGujarat Board SSC results announced: 82.56 pc pass percentage recorded

NationalThousands from Hyderabad head to Andhra Pradesh for voting